Control Samples Required for ELISA Protocol
Enzyme-Linked Immunosorbent Assay (ELISA) is a powerful analytical biochemistry assay that utilizes antibodies and color change to identify a substance. It is widely used in the field of immunology to detect the presence of antibodies or antigens in a sample. The accuracy and reliability of ELISA depend significantly on the use of appropriate control samples throughout the protocol. This article delves into the essential control samples required for ELISA to ensure the validity and reproducibility of the assay's results.
Positive and Negative Controls
- Positive Control
A positive control is an integral component of the ELISA protocol, serving as a benchmark to confirm that the assay is working as intended. This control comprises a sample known to contain the target antigen or antibody at a concentration that can be reliably detected by the assay. The presence of a positive signal from the positive control indicates the proper functioning of the ELISA reagents and protocol. It provides a reference point against which the test samples can be compared.
- Negative Control
Conversely, the negative control contains none of the target antigen or antibody. It is crucial for identifying any non-specific binding or background noise in the assay. A negative control helps in distinguishing between a true positive result and background signal, ensuring the specificity of the assay. This control is usually a buffer or serum that lacks the target analyte.
Standards
Standards are known concentrations of the analyte used to construct a calibration curve in quantitative ELISA assays. They enable the determination of the analyte concentration in test samples by comparing their signals to the standard curve. Standards must be treated in the same way as the test samples to ensure the accuracy of the quantitation.
Sample and Reagent Blanks
- Sample Blank
The sample blank, often referred to as the assay blank, contains all components of the assay except the analyte. It is used to adjust the spectrophotometer to zero absorbance, ensuring that any absorbance measured is due to the analyte of interest. The sample blank helps in correcting for the absorbance contributed by other components in the assay. - Reagent Blank
The reagent blank includes all reagents except the primary antibody (in the case of indirect ELISA) or antigen (in direct ELISA). This control is essential for identifying any non-specific interactions between the secondary antibody and the assay components, excluding the primary antibody-antigen interaction.
Spike-and-Recovery and Linearity-of-Dilution Controls
Conclusion
References
- Crowther, J.R., 2009. The ELISA guidebook. Humana Press.
- Lequin, R.M., 2005. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clinical Chemistry, 51(12), pp.2415-2418.
- Hantash, J., Smidt, M., & Bowsher, R. R. (2009). The development, optimization and validation of an ELISA bioanalytical method for the determination of Cetuximab in human serum. Analytical Methods, 1(2), 144-148.
- Hnasko, R., 2015. ELISA: Methods and Protocols. Methods in Molecular Biology, 1318.
- Minic, R., & Zivkovic, I. (2020). Optimization, validation and standardization of ELISA. In Norovirus (pp. 9-28). London, UK: IntechOpen.
- Engvall, E. and Perlmann, P., 1971. Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G. Immunochemistry, 8(9), pp.871-874.
- Aydin, S., 2015. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides, 72, pp.4-15.
Written by Tehreem Ali
Tehreem Ali completed her MS in Bioinformatics and conducted her research work at the IOMM lab at GCUF, Pakistan.
Recent Posts
-
Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy
Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the …17th Dec 2025 -
Enavatuzumab Biosimilar: Advancing TWEAKR-Targeted Therapy in Cancer
Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as …17th Dec 2025 -
Alemtuzumab Biosimilar: Advancing CD52-Targeted Therapy
Alemtuzumab is a monoclonal antibody targeting CD52, a glycoprotein highly expressed o …17th Dec 2025